A familial autosomal dominant form has also been reported. In a 2020 study, cryofibrinogenemia was detected in two-thirds of 54 patients with COVID chilblains. More studies are needed to confirm that cryofibrinogenemia is implicated in the pathogenesis of chilblains in COVID-19 patients.
Cryofibrinogenemia may be treatable and reversible, with a relatively prompt resolution of skin lesions with immunosuppressive therapy.
D89.2 – Hypergammaglobulinemia, unspecified
10934005 – Cryofibrinogenemia
Differential Diagnosis & Pitfalls
Drug Reaction Data